METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS
申请人:Snutch Terrance P.
公开号:US20090312346A1
公开(公告)日:2009-12-17
A method of increasing the bioavailability of a compound of formula 1 by orally administering to a patient a compound of formula 1, or a pharmaceutically acceptable salt thereof, with food:
Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
申请人:Children's Medical Center Corporation
公开号:US10729664B2
公开(公告)日:2020-08-04
The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.
本发明提供了用于治疗神经源性炎症的化合物、组合物、方法和试剂盒。
Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors
作者:Hassan Pajouhesh、Zhong-Ping Feng、Yanbing Ding、Lingyun Zhang、Hossein Pajouhesh、Jerrie-Lynn Morrison、Francesco Belardetti、Elizabeth Tringham、Eric Simonson、Todd W. Vanderah、Frank Porreca、Gerald W. Zamponi、Lester A. Mitscher、Terrance P. Snutch
DOI:10.1016/j.bmcl.2010.01.008
日期:2010.2
A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.
CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES